Sugi Predict

Sugi Predict / Compounds / SCHEMBL309963

SCHEMBL309963

SCHEMBL309963

N[C@H](C=O)Cc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX1 P07099 2/20 0.56
▸ TAAR1 Q96RJ0 3/20 0.52
▸ SLC6A2 P23975 2/20 0.52
▸ MAOA P21397 1/20 0.52
▸ SLC6A4 P31645 1/20 0.52
▸ SLC6A3 Q01959 1/20 0.52
▸ SIGMAR1 Q99720 1/20 0.52
▸ CYP2A6 P11509 1/20 0.52
▸ ADORA2A P29274 1/20 0.52
▸ ADORA1 P30542 1/20 0.52
▸ ALPI P09923 1/20 0.52
▸ PKM P14618 1/20 0.52
▸ PTGS1 P23219 1/20 0.52
▸ XIAP P98170 1/20 0.52
▸ SLC7A5 Q01650 1/20 0.52
▸ LAP3 P28838 3/20 0.48
▸ ANPEP P15144 2/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2639450 1.00 EPHX1 (0.56) EPHX1TAAR1SLC6A2MAOASLC6A4
SCHEMBL7327748 1.00 EPHX1 (0.56) EPHX1TAAR1SLC6A2MAOASLC6A4
SCHEMBL623688 1.00 EPHX1 (0.56) EPHX1TAAR1SLC6A2MAOASLC6A4
SCHEMBL6486058 1.00 EPHX1 (0.56) EPHX1TAAR1SLC6A2MAOASLC6A4
Hydrochloric Acid SCHEMBL5568008 0.98 EPHX1 (0.54) EPHX1TAAR1SLC6A2MAOASLC6A4
SCHEMBL8781479 0.98 EPHX1 (0.54) EPHX1TAAR1SLC6A2MAOASLC6A4
SCHEMBL6377106 0.90 EPHX1 (0.47) EPHX1TAAR1SLC6A2MAOASLC6A4
SCHEMBL6370405 0.90 EPHX1 (0.47) EPHX1TAAR1SLC6A2MAOASLC6A4
SCHEMBL24311844 0.90 SRR (0.50) EPHX1TAAR1SLC6A2MAOASLC6A4
SCHEMBL18647219 0.90 SRR (0.50) EPHX1TAAR1SLC6A2MAOASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1616 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024162639-A1 POLISHING SLURRY COMPOSITION 주식회사 케이씨텍 2024-08-08 — — WO claimed
EP-3436595-B1 OPTIMIZED MICROBIAL CELLS FOR PRODUCTION OF MELATONIN AND OTHER COMPOUNDS UNIV DANMARKS TEKNISKE (DK) 2024-02-28 — — EP claimed
EP-4313144-A1 COMBINATIONS COMPRISING ANTI-TM4SF1 ANTIBODIES AND IMMUNOTHERAPEUTIC AGENTS AND METHODS OF USING THE SAME Angiex, Inc. (US) 2024-02-07 — — EP claimed
WO-2024008941-A1 NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS LES LABORATOIRES SERVIER (FR) 2024-01-11 — — WO claimed
US-20230405124-A1 GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF IMMUNE SYSTEM DYSFUNCTION Oncotracker, Inc. 2023-12-21 — — US claimed
US-20230293713-A1 ANTI-TM4SF1 ANTIBODY DRUG CONJUGATES AND METHODS OF USING SAME ANGIEX, INC. 2023-09-21 — — US claimed
WO-2022204565-A1 COMBINATIONS COMPRISING ANTI-TM4SF1 ANTIBODIES AND IMMUNOTHERAPEUTIC AGENTS AND METHODS OF USING THE SAME ANGIEX, INC. (US) 2022-09-29 — — WO claimed
CN-114533945-A Two-dimensional MXene-inorganic organic hybrid multifunctional hydrogel for promoting healing of infectious diabetes wound and preparation method thereof 西北工业大学 2022-05-27 — — CN claimed
US-10906881-B2 Inhibitors of arginine gingipain Cortexyme, Inc. (US) 2021-02-02 — — US claimed
EP-3180390-B1 POLYMER FOR TISSUE ENGINEERING UNIV LINZ (AT) 2020-11-25 — — EP claimed
WO-1993016710-A1 PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME MERCK & CO., INC. (US) 1993-09-02 — — WO claimed
WO-1993014777-A1 PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME MERCK & CO., INC. (US) 1993-08-05 — — WO claimed
EP-0547699-A1 Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme MERCK & CO. INC. (US) 1993-06-23 — — EP claimed
EP-0519748-A2 Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme MERCK & CO. INC. (US) 1992-12-23 — — EP claimed
WO-1992014743-A2 ANTIVIRAL ACTIVITY AND RESOLUTION OF 2-HYDROXYMETHYL-5-(5-FLUOROCYTOSIN-1-YL)-1,3-OXATHIOLANE EMORY UNIVERSITY (US) 1992-09-03 — — WO claimed
EP-0237082-B1 3,5-DISUBSTITUTED 4,5-DIHYDROISOXAZOLES AS TRANSGLUTAMINASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1991-05-29 — — EP claimed
WO-1988005049-A1 NOVEL COMPOUNDS Aktiebolaget Hässle (SE) 1988-07-14 — — WO claimed
EP-0273893-A2 Novel compounds Aktiebolaget Hässle (SE) 1988-07-06 — — EP claimed
EP-0237082-A2 3,5-disubstituted 4,5-dihydroisoxazoles as transglutaminase inhibitors SYNTEX (U.S.A.) INC. (US) 1987-09-16 — — EP claimed
US-4415546-A STEROIDOGENICALL-ACTIVE POLYPEPTIDE; CORTICOIDS; HORMONES REGENTS OF THE UNIVERSITY OF CALIFORNIA THE 1983-11-15 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10906881-B2 Inhibitors of arginine gingipain ARGLU1, ENPEP, PRAP1 EPHX1 1584/4885TAAR1 4707/4885SLC6A2 4373/4885
US-20230293713-A1 ANTI-TM4SF1 ANTIBODY DRUG CONJUGATES AND METHODS OF USING SAME TM9SF4, TM9SF2, TM9SF3 EPHX1 2941/4885TAAR1 3489/4885SLC6A2 1593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.